May 26, 2015

The Food and Drug Administration has approved Boehringer Ingelheim, Inc.'s Stiolto Respimat (tiotropium bromide and olodaterol), a once-daily inhaler meant to treat obstructed airflow in patients, the company announced Tuesday. 

April 7, 2015

A new indication for Boehringer Ingelheim Pharmaceuticals's Pradaxa may be on the horizon. 

January 21, 2015

Boehringer Ingelheim Pharmaceuticals on Wednesday announced that its Spiriva Respimat (tiotropium bromide) inhalation spray is now available by prescription through pharmacies across the United States. 

 

October 31, 2014

Mylan on Friday announced the launch of nevirapine extended-release tablets in 400-mg strength, a generic version of Viramune XR from Boehringer Ingelheim. 

October 21, 2014

Boehringer Ingelheim Pharmaceuticals on Monday announced that Ofev (nintedanib) capsules are now available in the United States. Ofev was approved by the Food and Drug Administration on Oct. 15 to treat idiopathic pulmonary fibrosis.

October 8, 2014

Boehringer Ingelheim on Wednesday announced that its Striverdi Respimat (olodaterol) inhalation spray in 5-mcg dosage strength is now available by prescription in pharmacies across the United States. 

September 26, 2014

Boehringer Ingelheim Pharmaceuticals announced that the Food and Drug Administration approved Spiriva Respimat (tiotropium bromide) inhalation spray as a treatment for bronchospasm associated with chronic obstructive pulmonary disease. 

September 5, 2014

Univision on Thursday announced the official sponsors for its singing reality competition, “Va Por Ti” (This One’s For You) , a co-production of Televisa and Univision. 

August 26, 2014

Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Co. announced that Jardiance (empagliflozin) tablets are now available by prescription in pharmacies across the United States.

April 21, 2014

Boehringer Ingelheim Pharmaceuticals has announced that the Food and Drug Administration and European Commission have granted Orphan Drug Designation to volasertib for acute myeloid leukemia.

April 7, 2014

Boehringer Ingelheim Pharmaceuticals announced that the Food and Drug Administration has approved Pradaxa (dabigatran etexilate mesylate), which is used to treat deep venous thrombosis and pulmonary embolism.

February 7, 2014

The United States Hispanic Chamber of Commerce welcomed Boehringer Ingelheim Pharmaceuticals to its family of corporate members as a strategic partner.

January 28, 2014

Roxane Labs announced the launch of telmisartan tablets USP, an authorized generic version of Boehringer Ingelheim's Micardis tablets.

January 21, 2014

With the role of social media rapidly expanding, nearly half of pharmaceutical manufacturers are now actively using this channel to engage with patients on healthcare-related topics, according to a new report by the IMS Institute for Healthcare Informatics.

January 10, 2014

The Food and Drug Administration has approved a generic drug for high blood pressure made by Actavis, the company said Friday.

November 8, 2013

Boehringer Ingelheim SVP managed markets Jeff Huth has been elected by the National Pharmaceutical Council as chairman of the board for 2013-2014, the organization said Friday.

November 6, 2013

Many physicians in Asia say more information on managing Type 2 diabetes is needed, according to a new poll.

September 24, 2013

The global market for Type 2 diabetes will nearly double over the next six years, according to a new report.

September 9, 2013

Boehringer Ingelheim Consumer Health Care on Monday announced the introduction of Captain Zantac, the new face of the Zantac brand.

August 15, 2013

Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital on a long-term study program to assess comparative effectiveness and safety, as well as prescribing patterns, of oral anticoagulants, including Pradaxa, for the reduction of stroke risk in U.S. patients with non-valvular atrial fibrillation.

July 12, 2013

The Food and Drug Administration has approved a new lung cancer drug made by Boehringer Ingelheim, the agency said.

June 4, 2013

The Center for Healthcare Supply Chain Research, HDMA’s nonprofit research foundation, and Genentech on Tuesday honored Robert Belknap, executive director of trade sales and operations for Boehringer Ingelheim Pharmaceuticals, with the 2013 Nexus Award for Lifetime Achievement.

May 30, 2013

While the passage of the Patient Protection and Affordable Care Act of 2010 was a milestone in a number of respects, it also was one of the biggest moments in the history of the generic drug industry since the 1984 passage of the Hatch-Waxman Act, which created an abbreviated regulatory approval pathway for generic pharmaceutical drugs.

May 16, 2013

The makers of a pill bottle that uses wireless technology to keep patients adherent won the grand prize at a recent healthcare innovation contest.